Keyphrases
Programmed Death-ligand 1 (PD-L1)
100%
Myeloma
100%
Lymphodepletion
100%
T Cells
66%
Tumor Cells
33%
Irradiation
33%
PD-1 Blockade
33%
Anti-PD-1 Therapy
33%
Anti-PD-1
33%
Tumor Model
16%
Hematological Malignancies
16%
Multiple Myeloma
16%
Immune Response
16%
Tumor Immunology
16%
Tumor
16%
Bone Marrow
16%
CD8+ T Cells
16%
Antitumor Efficacy
16%
Early Phase Clinical Trials
16%
Cell Survival
16%
Clinical Testing
16%
CD4 T Cells
16%
Autoreactive T Cells
16%
Patient Survival
16%
T Cell Subsets
16%
Tumor Rejection
16%
Multiple Myeloma Patients
16%
Cell Transfer
16%
Antitumor Effect
16%
PD-1 Expression
16%
Nonmyeloablative
16%
Preactivated
16%
In Vivo Depletion
16%
Malignant Plasma Cells
16%
Solid Tumor Model
16%
Medicine and Dentistry
Death Receptor
100%
Myeloma
100%
Programmed Death 1 Receptor
100%
Programmed Death-Ligand 1
100%
T Cell
55%
Neoplasm
22%
Tumor Cell
22%
Tumor Model
22%
Multiple Myeloma
22%
Immunosuppressive Treatment
11%
Immunoreactivity
11%
Hematologic Malignancy
11%
Malignant Neoplasm
11%
Solid Malignant Neoplasm
11%
Transfer Cell
11%
T Cell Subset
11%
Tumor Rejection
11%
Immunoglobulin Producing Cell
11%
Clinical Trial
11%
Cytotoxic T-Cell
11%
T-Helper Cell
11%
Pharmacology, Toxicology and Pharmaceutical Science
Death Receptor
100%
Myeloma
100%
Programmed Death 1 Receptor
100%
Neoplasm
100%
Tumor Model
40%
Multiple Myeloma
40%
Clinical Trial
20%
Elimination
20%
Malignant Neoplasm
20%
Hematologic Malignancy
20%
CD8 Antigen
20%
Solid Malignant Neoplasm
20%
Immunology and Microbiology
Death Receptor
100%
Programmed Death-Ligand 1
100%
Programmed Death 1 Receptor
100%
T Cell
55%
Tumor Cell
22%
Multiple Myeloma
22%
T Cell Subset
11%
Immunosuppression
11%
Cytotoxic T-Cell
11%
T-Helper Cell
11%
Tumor Rejection
11%
Transfer Cell
11%
Immunoreactivity
11%
Immunoglobulin Producing Cell
11%